- Home
- BATL vs NEPH Comparison
BATL vs NEPH Comparison
Compare BATL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- NEPH
- Stock Information
- Founded
- BATL 1987
- NEPH 1997
- Country
- BATL United States
- NEPH United States
- Employees
- BATL N/A
- NEPH N/A
- Industry
- BATL Oil & Gas Production
- NEPH Medical/Dental Instruments
- Sector
- BATL Energy
- NEPH Health Care
- Exchange
- BATL Nasdaq
- NEPH Nasdaq
- Market Cap
- BATL 40.0M
- NEPH 36.1M
- IPO Year
- BATL N/A
- NEPH 2004
- Fundamental
- Price
- BATL $1.35
- NEPH $3.98
- Analyst Decision
- BATL
- NEPH Buy
- Analyst Count
- BATL 0
- NEPH 1
- Target Price
- BATL N/A
- NEPH $5.00
- AVG Volume (30 Days)
- BATL 3.1M
- NEPH 66.9K
- Earning Date
- BATL 08-13-2025
- NEPH 08-07-2025
- Dividend Yield
- BATL N/A
- NEPH N/A
- EPS Growth
- BATL N/A
- NEPH N/A
- EPS
- BATL N/A
- NEPH 0.08
- Revenue
- BATL $191,498,000.00
- NEPH $15,517,000.00
- Revenue This Year
- BATL N/A
- NEPH $17.06
- Revenue Next Year
- BATL N/A
- NEPH $12.20
- P/E Ratio
- BATL N/A
- NEPH $53.08
- Revenue Growth
- BATL N/A
- NEPH 10.34
- 52 Week Low
- BATL $1.05
- NEPH $1.36
- 52 Week High
- BATL $6.89
- NEPH $5.00
- Technical
- Relative Strength Index (RSI)
- BATL 43.09
- NEPH 55.90
- Support Level
- BATL $1.21
- NEPH $3.83
- Resistance Level
- BATL $3.21
- NEPH $4.39
- Average True Range (ATR)
- BATL 0.46
- NEPH 0.48
- MACD
- BATL -0.10
- NEPH -0.06
- Stochastic Oscillator
- BATL 5.69
- NEPH 40.35
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.